|Court:||United States District Court for the Southern District of Florida|
|Class Period:||09/26/2013 - 09/07/2018|
|Case Leader:||John Rizio-Hamilton|
|Case Team:||Jai K. Chandrasekhar|
Please note the Claim Form is no longer available.
Securities fraud class action filed on behalf of a class of investors who purchased or otherwise acquired OPKO Health Inc. (“OPKO”) common stock from September 26, 2013 to September 7, 2018, inclusive, and were damaged thereby (the "Class Period").
Lead Plaintiff Has Settled the Action for $16.5 Million
The Court-appointed Lead Plaintiff, The Amitim Funds, on behalf of itself and the Settlement Class, has settled the Action for $16,500,000 in cash (the “Settlement”).
The Court held a hearing to consider approval of the Settlement and related matters on December 15, 2020. On April 28 and 29, 2021, the Court entered a Final Judgment and an Order finally approving the Settlement and approving the proposed Plan of Allocation, and an Order awarding attorneys’ fees and expenses.
Please read the Notice to fully understand your rights. You may also visit the Settlement website, OPKOHealthSecuritiesLitigation.com, for more information about the Settlement.
Information in Hebrew (מידע בעברית) can be found at OPKOHealthSecuritiesLitigation.com.
If you purchased OPKO common stock only on the Tel Aviv Stock Exchange (“TASE”) you do not need to submit a Claim Form. Those Settlement Class Members will be eligible to receive a distribution from the Settlement based on the shares they purchased on the TASE without submitting a Claim Form.
In September 2018, after a significant investigation, the SEC charged Frost and OPKO with numerous violations of the federal securities laws for this misconduct. After the disclosure of the SEC complaint, the price of OPKO common stock collapsed by more than 30%, causing significant harm to OPKO shareholders. The Complaint alleges that Defendant Phillip Frost, CEO and Chairman of Defendant OPKO, who enjoyed a reputation as a savvy investor in biotechnology companies and was sometimes referred to as the “Warren Buffet of biotech,” used OPKO, a publicly traded company, as a vehicle for illicit investing activities. The action arises from alleged false statements and omissions by Frost and OPKO concealing the involvement of Frost, OPKO and other Defendants in multiple illicit “pump-and-dump” stock schemes. The Defendants allegedly used orchestrated trading and false promotional pieces to artificially “pump” up the share price of companies in which they had invested, and then “dumped” their shares by selling them to unsuspecting investors, leaving investors holding stock that was, in truth, virtually worthless.
In December 2013, investment company Lakewood Capital Management (“Lakewood”) published a detailed report titled, “OPKO Health: The Placebo Effect” (the “Lakewood Report”), which connected Frost and OPKO with two individuals named Barry Honig and Michael Brauser, among others, implicated in numerous suspect investments going back years. The Lakewood Report detailed examples of litigation against, and suspected fraud by, Honig and Brauser, and raised serious concern among OPKO investors. In the days after Lakewood’s criticisms were aired, OPKO’s stock declined significantly on elevated trading volume. Frost and Opko denied the allegations in the Lakewood Report.
Throughout the Class Period, Frost and OPKO made a host of other public statements in SEC filings, investor conferences, and the media that were designed to reassure investors that their investment activities were legitimate, were based on the identification of valuable medical technology, and were made to benefit OPKO and its shareholders.
The Complaint alleges, however, that these statements were materially false and misleading, and served to conceal a disturbing truth: unbeknownst to investors, Frost and OPKO were indeed involved in multiple alleged illicit “pump-and-dump” schemes with Honig and Brauser. Investors in OPKO stock did not learn the truth about this alleged misconduct until September 7, 2018, when the SEC charged Frost, OPKO, Honig, Brauser, and multiple additional entities controlled by Frost with a litany of violations of the federal securities laws for engaging in multiple “‘pump-and-dump’ schemes” leaving “retail investors holding virtually worthless shares.”
On February 4, 2019, the Court appointed The Amitim Funds as Lead Plaintiff, and BLB&G as Lead Counsel, for the Class, and on May 3, 2019, Lead Plaintiff filed the Complaint on behalf of a class of investors who purchased or otherwise acquired OPKO common stock from September 26, 2013 to September 7, 2018. In June 2020, the parties reached a proposed settlement of $16.5 million that was subject to Court approval.
On September 4, 2020, the Court entered an Order preliminarily approving the Settlement, approving the mailing of notice to the Settlement Class, and scheduling a final Settlement Hearing for December 15, 2020.
On April 28, 2021, the Court entered an Order finally approving the Settlement and approving the proposed Plan of Allocation. On April 29, 2021, the Court entered an Order awarding attorneys’ fees and expenses and a Final Judgment.
On March 23, 2022, the Court approved the distribution of the U.S. portion of the Net Settlement Fund to eligible Claimants and the initial distribution of funds occurred in May 2022.
- Events BLB&G Celebrates Women’s International Legal Efforts at NYCBA Conference March 24, 2023 Learn More
- Events BLB&G Partner Hannah Ross to Speak on “How Retirement Systems Drive Corporate Governance Reforms” at TEXPERS March 22, 2023 Learn More
- Publications “Section 11’s Tracing Doctrine Goes Up to the Supreme Court” by John C. Browne and Lauren Ormsbee Published in The Review of Securities & Commodities Regulation March 17, 2023 Learn More
- News BLB&G Trial Team Achieves Precedent-Setting Victory in Delaware Court of Chancery March 17, 2023 Learn More
- Events BLB&G Partner Christopher Orrico and Senior Counsel Thomas James Teach Seminar at Villanova University Charles Widger School of Law March 15, 2023 Learn More